Abivax (ABVX) Amortization (2024 - 2025)
Abivax (ABVX) recorded quarterly Amortization of $111.7 million in Q2 2025, down 26.35% quarter-over-quarter from $151.7 million in Q1 2025, and down 8.47% on a YoY basis from $122.1 million in Q2 2024.
Abivax (ABVX) Amortization (2024 - 2025) Analysis & Trends
Abivax's Amortization history runs 2 years deep, the most recent figure standing at $111.7 million for Q2 2025.
- In Q2 2025, Amortization fell 8.47% year-over-year to $111.7 million; the TTM figure through Jun 2025 stood at $111.7 million (down 8.47% YoY), while the FY2024 annual figure was $116.7 million, changed N/A from the prior year.
- Amortization was $111.7 million for Q2 2025 at Abivax, down from $151.7 million in the prior quarter.
- In the past five years, Amortization ranged from a high of $151.7 million in Q1 2025 to a low of $104.4 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 111.73 Mn |
| Jun 30, 2025 | 111.73 Mn |
| Mar 31, 2025 | 151.70 Mn |
| Mar 31, 2025 | 151.70 Mn |
| Dec 31, 2024 | 116.71 Mn |
| Dec 31, 2024 | 116.71 Mn |
| Jun 30, 2024 | 122.08 Mn |
| Jun 30, 2024 | 122.08 Mn |
| Mar 31, 2024 | 104.41 Mn |
| Mar 31, 2024 | 104.41 Mn |